Collecting blood samples from patients with active non-small cell lung cancer
Official title: Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
Run by Sanguine Biosciences · NCT05669105 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is collecting blood samples from people with active non-small cell lung cancer to see how their immune system responds and to help find new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Sanguine Biosciences Industry-sponsored |
| Locations | 1 site (Waltham, Massachusetts) |
| Trial ID | NCT05669105 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 100 who have been diagnosed with active non-small cell lung cancer and have associated tissue biomarker data.
✕Probably not a fit
Patients who are currently in remission or have a history of certain infectious diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect whole blood samples from individuals diagnosed with active non-small cell lung cancer (NSCLC) to investigate the immune response associated with the disease. By analyzing these samples, researchers hope to gain insights that could lead to the development of new treatments and therapies for lung cancer. Participants must provide informed consent and have relevant tissue biomarker data available. The study focuses on patients with adenocarcinoma or squamous cell carcinoma at any stage of the disease.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and therapies for patients with non-small cell lung cancer.
How similar studies have gone: While this approach is observational and focuses on biospecimen collection, similar studies have shown promise in understanding cancer biology and developing targeted therapies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants willing and able to provide written informed consent * Participants are willing and able to provide appropriate photo identification * Participant's age 18 - 100 years old * Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) * Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records Exclusion Criteria: * Participants who are pregnant or nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months * Participants currently enrolled in a clinical trial * Participants currently in remission
Where it's running
-
Sanguine Biosciences
Waltham, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Thomas Goslin
- Email: tgoslin@sanguinebio.com
- Phone: (818) 583-8844
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.